缅北强奸 News - Technologies for License /channels/news_feeds/all/term/Technologies%20for%20License/rss en Clarus Therapeutics and 缅北强奸 Announce Licensing Agreement to Develop and Commercialize Technology to Treat Coenzyme-Q10 Deficiencies /channels/channels/news/clarus-therapeutics-and-mcgill-university-announce-licensing-agreement-develop-and-commercialize-333414 <div class="field field-name-body field-type-text-with-summary field-label-hidden"><div class="field-items"><div class="field-item even"><p><em>Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to the wider class of mitochondrial diseases | An estimated 1 in 5,000 adults worldwide has a mitochondrial disease | Clarus to pay 缅北强奸 $350,000 upfront and up to $10.5 million in potential development and regulatory milestones</em></p></div></div></div><div class="field field-name-field-published-date field-type-datestamp field-label-hidden"><div class="field-items"><div class="field-item even"><div class="custom-multi-date"><div class="multi-date first"><span class="label">Published: </span><span class="day">16 </span><span class="month">September </span><span class="year">2021</span></div></div></div></div></div> Thu, 16 Sep 2021 13:12:57 +0000 webfull 173130 at /channels